Modulation of chemosensitivity by alpha interferon in multiple myeloma and non-Hodgkin's lymphoma

Rosario V. Iaffaioli, Gaetano Facchini, Anna Tortoriello, Stefania Scala, Roberto Pacelli, Giuseppe La Mura, Clorindo Pagliarulo, Giovanella Palmieri, Francesco Caponigro

Research output: Contribution to journalArticlepeer-review

Abstract

Low-grade non-Hodgkin's lymphoma and multiple myeloma are chemosensitive malignancies, but are rarely curable because of primary or acquired drug resistance. Interferon has been shown to modulate the multidrug resistance phenotype and to reinduce chemosensitivity in patients with chemoresistant tumors. Fifteen patients with multiple myeloma and 64 patients with low/intermediate grade non-Hodgkin's lymphoma unresponsive to initial chemotherapy were treated with alpha 2b interferon for 2 months. In case of an objective response, treatment was continued until disease progression; non-responding patients received the same chemotherapy to which they were resistant, preceded by a 5 day course of interferon. Interferon salvage monotherapy induced an objective response in 1/15 patients with multiple myeloma and in 7/64 patients with non-Hodgkin's lymphoma. An objective response was achieved after retreatment with first-line chemotherapy preceded by interferon in 4/14 patients (28.6%) with multiple myeloma and in 20/56 evaluable patients (35.7%) with non-Hodgkin's lymphoma. Toxicity was moderate, predictable, manageable, and never caused interruption of the treatment. Interferon appears to be able to modulate chemosensitivity of tumors refractory to chemotherapy with several potential mechanisms, including an effect on drug accumulation; its utilization in this setting warrants further evaluation.

Original languageEnglish
Pages (from-to)226-230
Number of pages5
JournalJournal of Experimental Therapeutics and Oncology
Volume1
Issue number4
Publication statusPublished - Jul 1996

Keywords

  • Alpha interferon
  • Drug resistance
  • Multiple myeloma
  • Non-Hodgkin's lymphoma

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology

Fingerprint Dive into the research topics of 'Modulation of chemosensitivity by alpha interferon in multiple myeloma and non-Hodgkin's lymphoma'. Together they form a unique fingerprint.

Cite this